Sign in
Taking peoplePhase 2

Carbon ion radiation after surgery for thymic tumors with leftover tumor

Tests carbon ion radiation in adults with thymic epithelial tumors after incomplete surgery.

Key facts

Who runs it
Jian Chen
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor
Status
Recruiting
Phase
Phase 2
People taking part
48 people, planned
Started
1 Jul 2025
Expected to end
28 Feb 2029
Type of study
Interventional
Treatments tested
  • Carbon ion radiotherapy
  • combined with platinum-based regimen
Record updated
13 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a thymic epithelial cancer (a cancer of the thymus gland in the chest) that is still visible after surgery. They will get carbon ion radiotherapy.

Age
18 to 70 years
Sex
All sexes
Disease stage
Stage II-IV (Masaoka-Koga) thymic epithelial cancer, confirmed by tissue test. Surgery left visible tumor behind (R2 resection). ECOG score of 0-2, meaning able to care for yourself. Expected to live at least 6 months.
Earlier treatment
Must have had surgery that left visible tumor. Cannot have had radiotherapy to the chest or radioactive seed implants before.

Main reasons for not taking part

  • Another cancer that is not under control
  • Large amount of fluid around the lungs or heart
  • Pacemaker or metal implants that may be affected by the radiation
  • Pregnancy or breastfeeding
  • HIV positive, active syphilis, or serious heart, lung or immune disease

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patients with stage II-IV (Masaoka-Koga) thymus epithelial malignancies without a history of thoracic radiotherapy who had undergone radical surgery (R2 resection, visible residual tumor) and had a definite pathological diagnosis
  • Sign informed consent
  • Between the ages of 18 and 70
  • ECOG general status score of 0-2
  • The expected survival is at least 6 months
  • Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109/L, platelet count ≥80 x 109/L, hemoglobin ≥9 g/dL 2). Lung function: FEV1>25%, DLCO>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin <1.5 times the upper limit of normal value, and AST, ALT<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml /min, and urinary protein <2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less

Who cannot take part

  • Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs
  • Chest radiation therapy or radioactive particle implantation history
  • HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis
  • Complicated with other malignant tumors that have not been controlled
  • Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area
  • A history of mental illness may hinder the completion of treatment
  • With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy
  • Pregnancy (confirmed by serum or urine β-HCG test) or lactation period
  • Have large quantity of pleural or pericardial effusion
  • Other circumstances that the physician considers inappropriate to participate in clinical study

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.

The group in the trial

  • Study armTreatment being tested

    The patients will receive 72GyE per 18 fractions of carbon ion radiotherapy. Patients with thymus cancer should be combined with platinum-based regimen (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin; paclitaxel combined with cisplatin or cisplatin / carboplatin / loplatin / nedaplatin; docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.

    Treatment: Carbon ion radiotherapy and combined with platinum-based regimen

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective Phase II Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymic Epithelial Malignant Tumor Received R2 Resection
Plain-language title
Carbon ion radiation after surgery for thymic tumors with leftover tumorGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06311955, who can take part
Record updated
13 June 2025